Kelun-Biotech announces fourth indication for Sacituzumab Tirumotecan (sac-TMT) approved by NMPA in HR+/HER2- breast cancer

DATROWAY Supplemental New Drug Application submitted in Japan for patients with metastatic triple negative breast...

First patient dosed for a Phase 1b/2 clinical trial of PD-L1 ADC HLX43 combination therapy...

Innovent dosed first participant in Phase 3 clinical study of IBI354 (novel HER2 ADC) for...

Niowave and Novartis enter global Actinium-225 supply agreement to advance next-generation cancer therapies

Chugai Pharmaceutical and Araris Biotech AG enter into license agreement for Araris’ linker-payload ADC technology,...